Lovastatin preserves renal function in experimental diabetes

American Journal of the Medical Sciences

Volumn 317, Issue 4, 1999, Pages 215-221

  Inman, Sharon R ^b,g   Stowe, N T ^a,d   Cressman, M D ^a,e   Brouhard, B H ^a,f   Nally Jr , J V ^a   Satoh, S ^c   Satodate, R ^c   Vidt, D G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f METROHEALTH MEDICAL CENTER   (United States)

^g LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetic nephropathy; Enalapril; Glomerular filtration rate; Kidney; Lovastatin; Renal circulation

Indexed keywords

ENALAPRIL; MEVINOLIN;

ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; INSULIN CLEARANCE; KIDNEY CIRCULATION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; NONHUMAN; RAT;

EID: 0033505904     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199904000-00001     Document Type: Article

References (32)

1. O'Donnell MP, Kasiske BL, Kim Y, et al. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kid Dis 1993;22:83-9.
2. Kasiske BL, O'Donnell MP, Garvis WJ, et al. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988;62:367-74.
3. Kasiske BL, O'Donnell MP, Clearly MP, et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667-72.
4. Harris KPG, Purkerson ML, Yates J, et al. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990;15:16-23.
5. O'Donnell MP, Kasiske BL, Katz SA, et al. Lovastatin but not enalapril reduces glomerular injury in Dahl-salt sensitive rats. Hypertension 1992;20:651-8.
6. Lee SK, Jin SY, Han DC, et al. Effects of delayed treatment with enalapril and lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993;8:1338-43.
7. Brouhard BH, Takamori H, Satoh S, et al. The combination of lovastatin and enalapril in a model of progressive renal disease. Ped Nephrol 1994;8:436-40.
8. Washio M, Nanishi F, Onoyama K, et al. Effects of antihyperlipidemic agent or dietary protein restriction on progressive renal deterioration in adriamycin-induced nephropathy in rats. Int Nephrol Urol 1993;25(3):295-303.
9. Guijarro C, Keane WF. Effects of lipids on the pathogenesis of progressive renal failure. Miner Electrolyte Metab 1996; 22:147-52.
10. Mulec H, Johnson SA, Bjorck S. Relationship between serum cholesterol and diabetic nephropathy. Lancet 1990; 1537-8.
11. Hafez KS, Inman SR, Stowe NT, Novick AC. The renal hemodynamic effects of lovastatin in a renal ablation model. Urol 1996;48:862-7.
12. Smith H. Principles of renal physiology. New York: Oxford University Press; 1965. p. 196-215.
13. Raij L, Azar S, Keane WF. Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats. Kidney Int 1984;26:137-43.
14. Sokal RR, Rohlf FJ. Biometry, 2nd ed. New York: Freeman; 1981.
15. D'Amico G, Gentile MG. Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients. Kidney Int Suppl 1991;31:S65-9.
16. Lam KSL, Cheng IKP, Janus ED, et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-9.
17. O'Donnell MP, Kasiske BL, Kim Y, et al. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83-7.
18. Aviram M, Danker G, Cogan U, et al. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism 1992;42:229-35.
19. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
20. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332: 488-93.
21. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993;119:969-76.
22. Stowe NT, Inman SR, Tapolyai M, et al. Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol 1996;156:249-52.
23. Glazer AA, Inman SR, Stowe, NT, et al. Renal microcirculatory effects of lovastatin in a rat model of reduced renal mass. Urology 1997;50:812-7.
24. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-74.
25. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410-5.
26. Allen TJ, Cooper ME, O'Brien RC, et al. Glomerular filtration rate in streptozotocin-induced diabetic rats. Diabetes 1990;39:1182-90.
27. Pohl MA. Changing the course of diabetic nephropathy: angiotensin converting enzyme inhibition in type I diabetic renal disease. Cleve Clin J Med 1994;61:38-42.
28. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacologic amelioration of glomerular capillary hypertension. J Clin Invest 1986;77: 1925-30.
29. O'Donnell MP, Kasiske BL, Keane WF. Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J 1988;2:2339-47.
30. Anderson S, Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526-36.
31. Fennel JP, Millard MM, Ashby MH. Proteinuria in the acutely diabetic rat and its responses to insulin treatment. Diabetologia 1981;21:54-7.
32. Zatz R, Meyer TW, Rennke HG, et al. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82:5963-7.